1 terminated. 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1 | Terminated 1 |
Follow Erin McCreary: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| UPMC OPTIMISE-C19 Trial, a COVID-19 Study Lilly Bamlanivimab, Regeneron Casirivimab + Imdevimab, Lilly Bamlanivimab + Etesevimab - Covid19 | Phase 4 | Terminated | Erin McCreary | 4571 | 2021-03-10 | 2023-06-15 |
COVID-19 (1)
bebtelovimab (1) · etesevimab (1) · imdevimab (1) · sotrovimab (1)
United States (1)
PMID 34034784, PMID 34473343, PMID 35697146, PMID 35713300, PMID 35834252